Tirzepatide is a groundbreaking therapeutic agent for individuals battling type 2 diabetes. As a dual agonist, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) https://mariamrivj703337.dsiblogger.com/73597295/tirzepatide-a-novel-glp-1-and-gip-receptor-agonist